Mary Lou Jepsen’s Post

Always the iconoclast Mary Lou Jepsen !!! Great points around affordability, distribution and pricing of the #StargateProject outputs. Humanity cannot wait, patients cannot wait. However, as the Human Genetics project has showed, the investment in R&D takes decades to payout. Be very wary of these #tech billionaires and there self-serving promises. Remember that Amazon, Microsoft , Oracle, Google , Alphabet Inc. have all “broken ships” on the rocky shoals of healthcare trying to innovate health records, health insurance, and to a lesser degree, biotech. Ever heard of Calico Life Sciences ? There is a reason you haven’t… There are possibilities of streamlining and speeding up in #pharma and #biotech however, there is no shortcut in R&D. #cancer #neurodegenerative #opensource #cardiovascular

Today is World Parkinson's Awareness Day. Increasingly, we evaluate innovations to help monitor and manage long term conditions. ▶️This case study examples a market assessment for a glove-based sensor technology, developed for Parkinson's patients to use at home. https://loom.ly/l3-tRa0 #MarketResearch #Innovation #MedTech #worldparkinsonsday

#JPM25 Has once again proven to be a hotbed of deal making and breaking news - but it isn't all biotech! We're here to break down the biggest #medtech stories from San Francisco this week! 🌉 🖥️ NVIDIA kicked off the year with a bang, announcing partnerships with IQVIA, Illumina, and Mayo Clinic as the tech giant cements its position in the #healthcare industry. 🛒 Dexcom CEO Kevin Sayer discussed the strategy for the company's first over-the-counter glucose sensor, Stelo. Dexcom are seeking extended coverage for users with type 2 #diabetes, while suggesting the technology may migrate towards a pre-diabetes or health and wellness platform. 📈 Boston Scientific upped its pulsed field ablation (#PFA) forecast, suggesting that 60% of atrial fibrillation (#AFib) procedures will be conducted with PFA globally by 2026. With CEO Mike Mahoney declaring the company a clear market leader. 🤖 Intuitive CEO Gary Guthart discussed plans for the Da Vinci 5 robotic surgical system roll out, with the company and its suppliers gearing up for a full launch across global regions this year. 💲 Medtronic CEO Geoff Martha told the #JPM crowd how Medtronic is stacking growth drivers, with #AFib, #diabetes, neurological conditions and #hypertension technologies all poised for rapid growth. 🏥 Renal Denervation may be poised for a significant boost with the Centers for Medicare & Medicaid Services begins #coverage analysis for Medtronic and Recor Medical devices. 🤝 Medtronic announced an agreement with Contego Medical, Inc. to become the exclusive distributor of the Contego Medical portfolio in the US, with the #deal including an option to buy the company. 📈 Guardant Health announced a 31% #revenue growth of $737M amidst the company's Shield™ screening blood test expansion Does the start of the year leave you optimistic for the year ahead? Or should scepticism remain for the medtech landscape? 💡❓

🔥 Big moves in PFA! Boston Scientific is poised to disrupt the status quo in the ablation catheter market, shifting dynamics in favor of pulsed field ablation (PFA) over traditional methods like radiofrequency (RFA) and cryoablation. 🎯 Electrophysiologists are buzzing with the potential of PFA, which is set to be embraced for over 30% of cases in the next year. This tech advancement is looking to not just disrupt, but 'cannibalize' the market shares of giants Abbott and J&J. 🚀 Here's the scoop: From a mere 6%, Boston Scientific's share could skyrocket to 16%+ in the U.S. market—all thanks to PFA's non-thermal approach to cardiac interventions. With an estimated $440 million up for grabs, it's not just a leap; it's a quantum jump for Boston Scientific's electrophysiology business. 📈 Medtronic might be taking part in this PFA race, but the shift's impact on their cryoablation share might just level the playing field. Meanwhile, Abbott and J&J are in the throes of the PFA wave, working furiously to not be left behind. 👀 The takeaway? Innovation is king, and for execs in MedTech, HealthTech, Pharmaceutical, and BioTech - it's essential to stay ahead of such transformative trends. And for my fellow tech leaders, let's closely watch this space. Who will emerge as the PFA frontrunner in this pulse-racing race? 🏁 #MedTechInnovation #PFA #BostonScientific Dominance

We are pleased that with the support of the BioMan4R2 programme, Time is Brain has achieved key milestones: BraiN20® has been validated for a broader patient population, including #ischaemic, #haemorrhagic and related #strokes. It has also demonstrated how the device can standardise and accelerate patient triage, expanding access to #Endovascular #Treatment. The potential to sustainably improve stroke treatments underlines TiB as a best practice example of innovation in the European #medical #technology ecosystem.

Exosomes are here to stay! 💪🏼 Since launching BENEV Exosomes into the market in 2017, there has been an explosion of Exosome Business in the U.S. 👇🏼Check out some of these stats: 2018 Exosome Market Share — $550k 2023 Exosome Market Share — $12M 💰Projected 2024 Exosome Market Share — $23M NOW is the time to do your research and review the different Exosome brands out there! If you swipe, you will see some compelling evidence that showcases the intensive research, clinical papers and studies that back up the science behind the @benevexosomes! No one else has an equivalent amount of clinical data and patents to support their product. PLUS, it has been used by over 1 Million U.S. patients. Want to schedule a meeting? 📲 DM us today and we would love to walk you through the power of BENEV Exosomes! #exosomes #benevexosomes #exosomecomplex #exosomeapplications #exosomesoothinggelmask #monarchaestheticservices

Developing a medical device can be daunting. Factors such as design considerations for patient safety, stringent regulatory requirements, lengthy approval processes, the need for clinical trials, and navigating complex market dynamics must be considered all while ensuring reliability and effectiveness. That's why you need a partner with a proven track record of successfully bringing new products to market. M4D specializes in concept to manufacturing medical devices as we guide you through every step of the process, providing unparalleled support and expertise along the way. From Art to Part....We have you Covered! Learn about proven processes and experience at: https://m4dllc.com/ #m4d #arttopart #neuro #neurovascular #endovascular #interventionalradiology #contractmanufacturing #asiamedtech #asiainnovation #prototyping #rapidprototyping #medicaldevicemanufacturing #researchanddevelopment #medtech #medicaldevice #startups #innovation #regulatory #quality

The novel science behind game-changing medical technology needs time and investment. That’s where Congress’ bipartisan Maintaining Investments in New Innovation Act comes in. Learn more about the #MINIAct:

Exosomes are here to stay! 💪🏼 Since launching BENEV Exosomes into the market in 2017, there has been an explosion of Exosome Business in the U.S. 👇🏼Check out some of these stats: 2018 Exosome Market Share — $550k 2023 Exosome Market Share — $12M 💰Projected 2024 Exosome Market Share — $23M NOW is the time to do your research and review the different Exosome brands out there! If you swipe, you will see some compelling evidence that showcases the intensive research, clinical papers and studies that back up the science behind the @benevexosomes! No one else has an equivalent amount of clinical data and patents to support their product. PLUS, it has been used by over 1 Million U.S. patients. Want to schedule a meeting? 📲 DM us today and we would love to walk you through the power of BENEV Exosomes! #exosomes #benevexosomes #exosomecomplex #exosomeapplications #exosomesoothinggelmask #monarchaestheticservices

🚀 Ground-breaking Trial Results Alert! 🩺💉 Some news in the HealthTech realm that's truly worth talking about. Cordis has just showcased phenomenal 2-year outcomes from their Selution SLR trial. Imagine a drug-eluting balloon that's setting new norms in vascular therapy - it's here, and it's proving its mettle! Offering hope for patients with femoral and popliteal artery disease, these DEB advancements might just be the beacon for endovascular therapies. With sustained drug release akin to stents and a whopping 83% primary patency rate at 24 months, we're looking at a 'Selution' that's not just smart, but showing incredible longevity. 💪 And here's a nod to innovation - those micro-reservoirs are playing the long game in drug delivery. For those affected by peripheral artery disease or looking for better post-stent options, this news could be game-changing. As a passionate tech headhunter, I'm thrilled to see such tech evolving and proving itself on such a critical stage. I often say it's the real-world impact that counts, and Selution SLR seems to be ticking some serious boxes in patient care. 👏 For fellow execs and innovators in the MedTech field, isn't this the kind of development that keeps our industry pulsing with potential? #HealthTech #Innovation #PatientCare